K4 Elite
K4 Elite
NMN is a nucleotide precursor in the NAD+ biosynthesis pathway, extensively studied in aging and metabolism research for its role in restoring cellular NAD+ levels in preclinical models.
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide formed from nicotinamide (a form of vitamin B3) and a ribose-phosphate group. It sits one enzymatic step upstream of nicotinamide adenine dinucleotide (NAD+), a coenzyme essential to energy metabolism and to the activity of NAD+-dependent enzymes.
Because cellular and tissue NAD+ levels are reported to decline with age in many model organisms, NMN has become one of the most heavily investigated NAD+ precursors in longevity and metabolic research. It is not a peptide; it is included in this reference library as a small-molecule metabolic compound frequently studied alongside longevity peptides.
A large body of preclinical work examines whether restoring NAD+ via NMN affects metabolic, vascular, and mitochondrial endpoints in cell and animal models.
NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT) enzymes as part of the NAD+ salvage pathway. By supplying this immediate precursor, studies report that NMN administration raises tissue NAD+ concentrations in laboratory models, in turn supporting the activity of NAD+-consuming enzymes such as sirtuins and PARPs.
Research has also examined how cells take up NMN, including reports of a specific transporter (Slc12a8) described in mouse intestine, a finding investigators use to explain observed increases in NAD+ following oral NMN exposure in animal studies.
Mills and colleagues (2016, Cell Metabolism) reported a long-term study administering NMN in drinking water to mice over 12 months, describing measured effects on body weight, energy metabolism, insulin sensitivity, and mitochondrial parameters relative to controls, as endpoints in that animal model.
Yoshino, Baur, and Imai (2018, Cell Metabolism) reviewed the preclinical NAD+-precursor literature, summarizing rodent studies in which NMN raised tissue NAD+ and altered metabolic markers, and outlining early human translational research.
Irie and colleagues (2020, Endocrine Journal) reported a first-in-human single-administration study evaluating the safety and metabolism of NMN in healthy men, describing pharmacokinetic and clinical-chemistry measurements as the study endpoints without establishing any therapeutic indication.
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
References are being compiled for this entry.